Shukra Pharma Shares Hit 5% Lower Circuit as Q4 PAT Declines 95% YoY

Synopsis: Shukra Pharmaceuticals Limited reported a weak Q4FY26 performance with total income declining around 49.4 percent year-on-year to Rs. 7.25 crore, while the company slipped into a net loss of Rs. 1.73 crore. Rising costs, lower operating income, and deferred tax impact weighed heavily on profitability during the quarter.

Shukra Pharmaceuticals has a total market capitalization of Rs. 1495.36 crore, according to data on the BSE stock has fallen 5 percent today. Sukra’s shares were trading at Rs. 34.15 apiece on the Bombay Stock Exchange; the stock has gained around 13.89 percent over the last five sessions, while it has declined about 3.39 percent in the 30 days. Over a six-month period, the stock has given a negative return of 14.87 percent, whereas on a year-on-year basis it has gone up nearly 163 percent, reflecting mixed overall performance. The stock’s 52-week high was Rs. 65.26 and 52-week low was Rs. 11.74.

Shukra Pharmaceuticals Limited reported a weak set of standalone results for the quarter ended March 31, 2026, impacted by a sharp decline in revenue and pressure on profitability. The company posted total income from operations of Rs. 7.25 crore in Q4FY26 compared to Rs. 14.37 crore reported in Q4FY25, reflecting a steep decline of around 49.5 percent year-on-year. Sequentially, revenue also declined sharply from Rs. 39.95 crore reported in Q3FY26, indicating a significant slowdown in business activity during the quarter.

Revenue from operations stood at Rs. 6.30 crore in Q4FY26 compared to Rs. 13.27 crore in Q4FY25, reflecting a decline of approximately 52.5 percent year-on-year. The company also reported net income from operations of Rs. 6.30 crore compared to Rs. 13.27 crore during the same period last year.

On the profitability front, the company slipped into a net loss of Rs. 1.73 crore in Q4FY26 compared to a profit of Rs. 5.39 crore reported in Q4FY25. Sequentially, the decline was even sharper compared to the profit of Rs. 20.36 crore reported in Q3FY26. The deterioration in profitability was mainly due to lower revenue generation, weaker operating performance, and a significant deferred tax adjustment during the quarter.

Profit before tax stood at Rs. 0.37 crore in Q4FY26 compared to Rs. 7.57 crore in Q4FY25, reflecting a sharp decline of around 95 percent year-on-year. This indicates substantial weakness in the company’s core operational performance during the quarter.

A major factor affecting profitability was the deferred tax charge. The company reported a deferred tax expense of Rs. 2.33 crore during the quarter compared to a deferred tax credit in the previous year period. This tax adjustment significantly impacted the bottom-line and pushed the company into losses despite remaining marginally profitable at the operating level.

For the full financial year FY26, the company reported total income of Rs. 61.29 crore compared to Rs. 36.79 crore in FY25, reflecting strong growth of around 66.6 percent. Profit before tax for FY26 stood at Rs. 28.77 crore compared to Rs. 13.34 crore in FY25, indicating healthy yearly operational growth.

Net profit for FY26 increased significantly to Rs. 22.05 crore compared to Rs. 9.58 crore in FY25, reflecting strong growth of around 130 percent despite the weak Q4 performance. Earnings per share (EPS) for FY26 improved to Rs. 0.50 compared to Rs. 0.22 in FY25.

The company also highlighted that it has entered into the manufacturing and trading business of “Shukra MedTech” effective from October 1, 2025, which may support diversification and additional growth opportunities going forward.

From an industry perspective, India’s pharmaceutical industry continues to benefit from growing domestic healthcare demand, rising exports, increasing chronic disease treatment, and expanding generic medicine opportunities. However, companies in the sector continue to face pricing pressure, regulatory compliance costs, and volatility in raw material prices.

Overall, the Q4FY26 results indicate short-term operational weakness for Shukra Pharmaceuticals due to lower revenue and tax-related impacts. Going forward, execution in the newly added MedTech business, revenue recovery, and margin improvement will remain key factors influencing the company’s future performance.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Shukra Pharma Shares Hit 5% Lower Circuit as Q4 PAT Declines 95% YoY appeared first on Trade Brains.